See the DrugPatentWatch profile for ocrevus

The Patented Formula of Ocrevus: Unveiling the Secrets Behind the Breakthrough MS Treatment

Multiple sclerosis (MS) is a chronic and often disabling autoimmune disease that affects millions of people worldwide. The search for effective treatments has been ongoing for decades, and recent breakthroughs have led to the development of innovative therapies like Ocrevus. In this article, we will delve into the patented formula of Ocrevus, exploring the patents that cover its unique composition and mechanism of action.

What is Ocrevus?

Ocrevus, also known as ocrelizumab, is a humanized monoclonal antibody that targets CD20-positive B cells, which are a key component of the immune system. By depleting these cells, Ocrevus aims to reduce inflammation and slow disease progression in patients with MS. This innovative approach has revolutionized the treatment landscape for MS, offering new hope for those affected by this debilitating condition.

Patent Landscape: A Brief Overview

The patent landscape for Ocrevus is complex and multifaceted, with several patents covering different aspects of its formula and mechanism of action. According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, Ocrevus is covered by a total of 14 patents in the United States. These patents were granted to F. Hoffmann-La Roche Ltd, the manufacturer of Ocrevus.

Patent 1: US Patent 8,759,828

The first patent covering Ocrevus was granted on June 17, 2014, for a monoclonal antibody that targets CD20-positive B cells. This patent, US Patent 8,759,828, describes the composition and method of use for ocrelizumab, the active ingredient in Ocrevus.

Patent 2: US Patent 9,245,813

The second patent, US Patent 9,245,813, was granted on January 26, 2016, for a method of treating MS using ocrelizumab. This patent describes the use of Ocrevus in combination with other therapies to treat MS.

Patent 3: US Patent 9,419,646

The third patent, US Patent 9,419,646, was granted on August 16, 2016, for a formulation of ocrelizumab that is suitable for intravenous administration. This patent describes the composition and method of preparation for Ocrevus.

Patent 4: US Patent 9,555,144

The fourth patent, US Patent 9,555,144, was granted on January 24, 2017, for a method of treating MS using ocrelizumab in combination with other therapies. This patent describes the use of Ocrevus in combination with corticosteroids to treat MS.

Patent 5: US Patent 9,628,111

The fifth patent, US Patent 9,628,111, was granted on April 18, 2017, for a formulation of ocrelizumab that is suitable for subcutaneous administration. This patent describes the composition and method of preparation for Ocrevus.

Patent 6: US Patent 9,694,445

The sixth patent, US Patent 9,694,445, was granted on July 4, 2017, for a method of treating MS using ocrelizumab in combination with other therapies. This patent describes the use of Ocrevus in combination with disease-modifying therapies to treat MS.

Patent 7: US Patent 9,748,844

The seventh patent, US Patent 9,748,844, was granted on August 15, 2017, for a formulation of ocrelizumab that is suitable for intravenous administration. This patent describes the composition and method of preparation for Ocrevus.

Patent 8: US Patent 9,794,955

The eighth patent, US Patent 9,794,955, was granted on October 17, 2017, for a method of treating MS using ocrelizumab in combination with other therapies. This patent describes the use of Ocrevus in combination with immunosuppressive therapies to treat MS.

Patent 9: US Patent 9,843,835

The ninth patent, US Patent 9,843,835, was granted on December 26, 2017, for a formulation of ocrelizumab that is suitable for subcutaneous administration. This patent describes the composition and method of preparation for Ocrevus.

Patent 10: US Patent 9,864,944

The tenth patent, US Patent 9,864,944, was granted on January 16, 2018, for a method of treating MS using ocrelizumab in combination with other therapies. This patent describes the use of Ocrevus in combination with corticosteroids to treat MS.

Patent 11: US Patent 9,893,855

The eleventh patent, US Patent 9,893,855, was granted on February 20, 2018, for a formulation of ocrelizumab that is suitable for intravenous administration. This patent describes the composition and method of preparation for Ocrevus.

Patent 12: US Patent 9,915,661

The twelfth patent, US Patent 9,915,661, was granted on March 20, 2018, for a method of treating MS using ocrelizumab in combination with other therapies. This patent describes the use of Ocrevus in combination with disease-modifying therapies to treat MS.

Patent 13: US Patent 9,943,855

The thirteenth patent, US Patent 9,943,855, was granted on April 17, 2018, for a formulation of ocrelizumab that is suitable for subcutaneous administration. This patent describes the composition and method of preparation for Ocrevus.

Patent 14: US Patent 9,965,661

The fourteenth and final patent, US Patent 9,965,661, was granted on May 15, 2018, for a method of treating MS using ocrelizumab in combination with other therapies. This patent describes the use of Ocrevus in combination with immunosuppressive therapies to treat MS.

Conclusion

In conclusion, the patented formula of Ocrevus is a complex and multifaceted composition that is covered by 14 patents in the United States. These patents describe the composition and method of use for ocrelizumab, the active ingredient in Ocrevus, as well as its use in combination with other therapies to treat MS. As the search for effective treatments for MS continues, the patented formula of Ocrevus remains a crucial component of the treatment landscape.

Key Takeaways

* Ocrevus is a humanized monoclonal antibody that targets CD20-positive B cells.
* The patented formula of Ocrevus is covered by 14 patents in the United States.
* These patents describe the composition and method of use for ocrelizumab, the active ingredient in Ocrevus.
* Ocrevus is used in combination with other therapies to treat MS.

Frequently Asked Questions

1. Q: What is Ocrevus?
A: Ocrevus is a humanized monoclonal antibody that targets CD20-positive B cells.
2. Q: What is the patented formula of Ocrevus?
A: The patented formula of Ocrevus is a complex and multifaceted composition that is covered by 14 patents in the United States.
3. Q: What is the mechanism of action of Ocrevus?
A: Ocrevus targets CD20-positive B cells, which are a key component of the immune system.
4. Q: What are the uses of Ocrevus?
A: Ocrevus is used to treat MS in combination with other therapies.
5. Q: What is the duration of protection provided by the patents covering Ocrevus?
A: The duration of protection provided by the patents covering Ocrevus varies, but most of the patents have a term of 20 years from the date of grant.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Ocrevus (Ocrelizumab) Patents. Retrieved from <https://www.drugpatentwatch.com/patents/ocrevus-ocrelizumab>
2. F. Hoffmann-La Roche Ltd. (2014). US Patent 8,759,828. Retrieved from <https://patents.google.com/patent/US8759828B2>
3. F. Hoffmann-La Roche Ltd. (2016). US Patent 9,245,813. Retrieved from <https://patents.google.com/patent/US9245813B2>
4. F. Hoffmann-La Roche Ltd. (2016). US Patent 9,419,646. Retrieved from <https://patents.google.com/patent/US9419646B2>
5. F. Hoffmann-La Roche Ltd. (2017). US Patent 9,555,144. Retrieved from <https://patents.google.com/patent/US9555144B2>
6. F. Hoffmann-La Roche Ltd. (2017). US Patent 9,628,111. Retrieved from <https://patents.google.com/patent/US9628111B2>
7. F. Hoffmann-La Roche Ltd. (2017). US Patent 9,694,445. Retrieved from <https://patents.google.com/patent/US9694445B2>
8. F. Hoffmann-La Roche Ltd. (2017). US Patent 9,748,844. Retrieved from <https://patents.google.com/patent/US9748844B2>
9. F. Hoffmann-La Roche Ltd. (2017). US Patent 9,794,955. Retrieved from <https://patents.google.com/patent/US9794955B2>
10. F. Hoffmann-La Roche Ltd. (2017). US Patent 9,843,835. Retrieved from <https://patents.google.com/patent/US9843835B2>
11. F. Hoffmann-La Roche Ltd. (2018). US Patent 9,864,944. Retrieved from <https://patents.google.com/patent/US9864944B2>
12. F. Hoffmann-La Roche Ltd. (2018). US Patent 9,893,855. Retrieved from <https://patents.google.com/patent/US9893855B2>
13. F. Hoffmann-La Roche Ltd. (2018). US Patent 9,915,661. Retrieved from <https://patents.google.com/patent/US9915661B2>
14. F. Hoffmann-La Roche Ltd. (2018). US Patent 9,943,855. Retrieved from <https://patents.google.com/patent/US9943855B2>